Molecular Imaging for Depressive Disorders

References

1. 1.↵
   1. Mankoff DA

   . A definition of molecular imaging. J Nucl Med 2007;48:18N, 21N

   FREE Full Text
2. 2.↵
   1. Weissleder R,
   2. Mahmood U

   . Molecular imaging. Radiology 2001;219:316–33

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Kang JH,
   2. Chung JK

   . Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008;49:164S–179S

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Kessler RC,
   2. Berglund P,
   3. Demler O,
   4. et al

   . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095–105

   CrossRefPubMedWeb of Science
5. 5.↵
   American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, Virginia: American Psychiatric Association; 2013
6. 6.↵
   American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, Virginia: American Psychiatric Association; 2000
7. 7.↵
   1. Charney DS,
   2. Sklar P,
   3. Buxbaum JD,
   4. et al.

   1. Duman RS

   . Molecular and cellular pathogenesis of depression and mechanisms for treatment response. In: Charney DS, Sklar P, Buxbaum JD, et al., eds. Neurobiology of Mental Illness. 4th ed. New York: Oxford University Press; 2013:425–37
8. 8.↵
   1. Charney DS

   . Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59(suppl 14):11–14
9. 9.↵
   1. Heninger GR,
   2. Delgado PL,
   3. Charney DS

   . The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996;29:2–11

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Jacobsen JP,
    2. Medvedev IO,
    3. Caron MG

    . The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse. Philos Trans R Soc Lond B Biol Sci 2012;367:2444–59

    Abstract/FREE Full Text
11. 11.↵
    1. Schlaepfer TE,
    2. Nemeroff CB

    1. Pariante CM,
    2. Nemeroff CB

    . Unipolar depression. In: Schlaepfer TE, Nemeroff CB , eds. Handbook of Clinical Neurology: Neurobiology of Psychiatric Disorders. Amsterdam, the Netherlands: Elsevier; 2012:239–49
12. 12.↵
    1. Brambilla P,
    2. Perez J,
    3. Barale F,
    4. et al

    . GABAergic dysfunction in mood disorders. Mol Psychiatry 2003;8:721–37, 715

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Petty F

    . Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease. Clin Chem 1994;40:296–302

    Abstract/FREE Full Text
14. 14.↵
    1. Sanacora G,
    2. Mason GF,
    3. Rothman DL,
    4. et al

    . Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002;159:663–65

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Möhler H

    . The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012;62:42–53

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Maciag D,
    2. Hughes J,
    3. O'Dwyer G,
    4. et al

    . Reduced density of calbindin immuno-reactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010;67:465–70

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Karolewicz B,
    2. Maciag D,
    3. O'Dwyer G,
    4. et al

    . Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 2010;13:411–20

    Abstract/FREE Full Text
18. 18.↵
    1. Serafini G,
    2. Pompili M,
    3. Innamorati M,
    4. et al

    . Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr Pharm Des 2013;19:1898–922

    CrossRefPubMed
19. 19.↵
    1. Pfleiderer B,
    2. Michael N,
    3. Erfurth A,
    4. et al

    . Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 2003;122:185–92

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Petrie RXA,
    2. Reid IC,
    3. Stewart CA

    . The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder: a critical review. Pharmacol Ther 2000;87:11–25

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Agarwal N,
    2. Port JD,
    3. Bazzocchi M,
    4. et al

    . Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 2010;255:23–41

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Ng F,
    2. Berk M,
    3. Dean O,
    4. et al

    . Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851–76

    Abstract/FREE Full Text
23. 23.↵
    1. Siwek M,
    2. Sowa-Kucma M,
    3. Dudek D,
    4. et al

    . Oxidative stress markers in affective disorders. Pharmacol Rep 2013;65:1558–71

    PubMed
24. 24.↵
    1. Palta P,
    2. Samuel LJ,
    3. Miller ER,
    4. et al

    . Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med 2014;76:12–19

    Abstract/FREE Full Text
25. 25.↵
    1. Yanik M,
    2. Erel O,
    3. Kati M

    . The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatr 2004;16:200–03

    CrossRef
26. 26.↵
    1. Chung CP,
    2. Schmidt D,
    3. Stein CM,
    4. et al

    . Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Res 2013;206:213–16

    CrossRefPubMed
27. 27.↵
    1. Michel TM,
    2. Frangou S,
    3. Thiemeyer D,
    4. et al

    . Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder: a postmortem study. Psychiatry Res 2007;151:145–50

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Kotan VO,
    2. Sarandol E,
    3. Kirhan E,
    4. et al

    . Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1284–90

    CrossRefPubMed
29. 29.↵
    1. Sarandol A,
    2. Sarandol E,
    3. Eker SS,
    4. et al

    . Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007;22:67–73

    CrossRefPubMed
30. 30.↵
    1. Drevets WC,
    2. Price JL,
    3. Simpson JR Jr.,
    4. et al

    . Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824–27

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Beyer JL,
    2. Krishnan KR

    . Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002;4:89–104

    PubMed
32. 32.↵
    1. Lee AL,
    2. Olge WO,
    3. Robert M

    . Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 2002;4:117–28

    CrossRef
33. 33.↵
    1. Wang L,
    2. Hermens DF,
    3. Hickie IB,
    4. et al

    . A systematic review of resting-state functional-MRI studies in major depression. J Affect Disorders 2012;142:6–12

    CrossRefPubMed
34. 34.↵
    1. Payne GS,
    2. Leach MO

    . Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol 2006;(79 spec no 1):S16–26
35. 35.↵
    1. van der Graaf M

    . In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J 2010;39:527–40

    CrossRefPubMed
36. 36.↵
    1. Charney DS,
    2. Sklar P,
    3. Buxbaum JD,
    4. Nestler EJ

    1. Lu H,
    2. Yang Y,
    3. Liu P

    . Brain imaging methodologies. In: Charney DS, Sklar P, Buxbaum JD, Nestler EJ , eds. Neurobiology of Mental Illness. 4th ed. New York: Oxford University Press; 2013:199–211
37. 37.↵
    1. Lyoo IK,
    2. Renshaw PF

    . Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 2002;51:195–207

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Krishna KR,
    2. Doraiswamy PM

    1. Moore CM,
    2. Renshaw PF

    . Magnetic resonance spectroscopy studies of affective disorders. In: Krishna KR, Doraiswamy PM , eds. Brain Imaging in Clinical Psychiatry. New York: Marcel Decker; 1997:185–214
39. 39.↵
    1. Bolo NR,
    2. Hodé Y,
    3. Nédélec JF,
    4. et al

    . Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000;23:428–38

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Miner CM,
    2. Davidson JRT,
    3. Potts NLS,
    4. et al

    . Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 1995;38:696–98

    CrossRefPubMed
41. 41.↵
    1. Strauss WL,
    2. Unis AS,
    3. Cowan C,
    4. et al

    . Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 2002;159:755–60

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Wolters M,
    2. Mohades SG,
    3. Hackeng TM,
    4. et al

    . Clinical perspectives of hybrid proton-fluorine magnetic resonance imaging and spectroscopy. Invest Radiol 2013;48:341–50

    CrossRefPubMed
43. 43.↵
    1. Iosifescu DV,
    2. Renshaw PF

    . 31P-Magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergic mechanism in depression. Harv Rev Psychiatry 2003;11:51–63

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Soares JC,
    2. Krishnan KR,
    3. Keshavan MS

    . Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Depression 1996;4:14–30
45. 45.↵
    1. Yildiz A,
    2. Sachs GS,
    3. Dorer DJ,
    4. et al

    . 31P nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatry Res 2001;106:181–91

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Volz HP,
    2. Rzanny R,
    3. Riehemann S,
    4. et al

    . 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 1998;248:289–95

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Harper DG,
    2. Jensen JE,
    3. Ravichandran C,
    4. et al

    . Tissue-specific differences in brain phosphodiesters in late-life major depression. Am J Geriatr Psychiatry 2013 Jan 11. [Epub ahead of print]
48. 48.↵
    1. Rauch SL,
    2. Renshaw PF

    . Clinical neuroimaging in psychiatry. Harv Rev Psychiatry 1995;2:297–312

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Kusumakar V,
    2. MacMaster FP,
    3. Gates L,
    4. et al

    . Left medial temporal cytosolic choline in early onset depression. Can J Psychiatry 2001;46:959–64

    PubMedWeb of Science
50. 50.↵
    1. Yildiz-Yesiloglu A,
    2. Ankerst DP

    . Review of ¹H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006;147:1–25

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Griffin JL,
    2. Bollard M,
    3. Nicholson JK,
    4. et al

    . Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1) HNMR spectroscopy. NMR Biomed 2002;15:375–84

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Wolfson M,
    2. Bersudsky Y,
    3. Hertz E,
    4. et al

    . A model of inositol compartmentation in astrocytes based upon efflux kinetics and slow inositol depletion after uptake inhibition. Neurochem Res 2000;25:977–82

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Frey R,
    2. Metzler D,
    3. Fischer P,
    4. et al

    . Myo-inositol in depressive and healthy subjects determined by frontal ¹H-magnetic resonance spectroscopy at 1.5 Tesla. J Psychiatr Res 1998;32:411–20

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Rao NP,
    2. Venkatasubramanian G,
    3. Gangadhar BN

    . Proton magnetic resonance spectroscopy in depression. Indian J Psychiatry 2011;53:307–11

    CrossRefPubMed
55. 55.↵
    1. Caverzasi E,
    2. Pichiecchio A,
    3. Poloni GU,
    4. et al

    . Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature. Funct Neurol 2012;27:13–22

    PubMed
56. 56.↵
    1. Auer DP,
    2. Putz B,
    3. Kraft E,
    4. et al

    . Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47:305–13

    CrossRefPubMedWeb of Science
57. 57.↵
    1. Mirza Y,
    2. Tang J,
    3. Russell A,
    4. et al

    . Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 2004;43:341–48

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Michael N,
    2. Erfurth A,
    3. Ohrmann P,
    4. et al

    . Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 2003;33:1277–84

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Sanacora G,
    2. Gueorguieva R,
    3. Epperson CN,
    4. et al

    . Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705–13

    CrossRefPubMedWeb of Science
60. 60.↵
    1. Yüksel C,
    2. Öngür D

    . Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010;68:785–94

    CrossRefPubMedWeb of Science
61. 61.↵
    1. Sanacora G,
    2. Mason GF,
    3. Rothman DL,
    4. et al

    . Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999;56:1043–47

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Hasler G,
    2. van der Veen JW,
    3. Tumonis T,
    4. et al

    . Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007;64:193–200

    CrossRefPubMedWeb of Science
63. 63.↵
    1. Bhagwagar Z,
    2. Wylezinska M,
    3. Jezzard P,
    4. et al

    . Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008;11:255–60

    Abstract/FREE Full Text
64. 64.↵
    1. Mu J,
    2. Xie P,
    3. Yang ZS,
    4. et al

    . ¹H magnetic resonance spectroscopy study of thalamus in treatment resistant depressive patients. Neurosci Lett 2007;425:49–52

    CrossRefPubMed
65. 65.↵
    1. Vythilingam M,
    2. Charles HC,
    3. Tupler LA,
    4. et al

    . Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. Biol Psychiatry 2003;54:744–50

    CrossRefPubMedWeb of Science
66. 66.↵
    1. Delgado y Palacios RD,
    2. Campo A,
    3. Henningsen K,
    4. et al

    . Magnetic resonance imaging and spectroscopy reveal differential hippocampal changes in anhedonic and resilient subtypes of the chronic mild stress rat model. Biol Psychiatry 2011;70:449–57

    CrossRefPubMedWeb of Science
67. 67.↵
    1. Hemanth Kumar BS,
    2. Mishra SK,
    3. Rana P,
    4. et al

    . Neurodegenerative evidences during early onset of depression in CMS rats as detected by proton magnetic resonance spectroscopy at 7T. Behav Brain Res 2012;232:53–59

    CrossRefPubMed
68. 68.↵
    1. Xi G,
    2. Hui J,
    3. Zhang Z,
    4. et al

    . Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by ¹H-MRS. PLoS One 2011;6:e28686

    CrossRefPubMed
69. 69.↵
    1. Czéh B,
    2. Michaelis T,
    3. Watanabe T,
    4. et al

    . Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001;98:12796–801

    Abstract/FREE Full Text
70. 70.↵
    1. Perrine SA,
    2. Ghoddoussi F,
    3. Michaels MS,
    4. et al

    . Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T ¹H-MRS study in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013 Nov 15. [Epub ahead of print]
71. 71.↵
    1. Renshaw PF,
    2. Parow AM,
    3. Hirashima F,
    4. et al

    . Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001;158:2048–55

    CrossRefPubMedWeb of Science
72. 72.↵
    1. Smith DF,
    2. Jakobsen S

    . Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 2009;19:611–28

    CrossRefPubMed
73. 73.↵
    1. Smith DF,
    2. Jakobsen S

    . Molecular neurobiology of depression: PET findings on the elusive correlation with symptom severity. Front Psychiatry 2013;4:8

    PubMed
74. 74.↵
    1. Savitz JB,
    2. Drevets WC

    . Neuroreceptor imaging in depression. Neurobiol Dis 2013;52:49–65

    CrossRefPubMed
75. 75.↵
    1. Oquendo MA,
    2. Hastings RS,
    3. Huang YY,
    4. et al

    . Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry 2007;64:201–08

    CrossRefPubMedWeb of Science
76. 76.↵
    1. Parsey RV,
    2. Hastings RS,
    3. Oquendo MA,
    4. et al

    . Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006;163:52–58

    CrossRefPubMedWeb of Science
77. 77.↵
    1. Reivich M,
    2. Amsterdam JD,
    3. Brunswick DJ,
    4. et al

    . PET brain imaging with [¹¹C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 2004;82:321–27

    CrossRefPubMedWeb of Science
78. 78.↵
    1. Reimold M,
    2. Knobel A,
    3. Rapp MA,
    4. et al

    . Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) 2011;213:563–72

    CrossRef
79. 79.↵
    1. Reimold M,
    2. Batra A,
    3. Knobel A,
    4. et al

    . Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry 2008;13:606–13, 55

    CrossRefPubMedWeb of Science
80. 80.↵
    1. Cannon DM,
    2. Ichise M,
    3. Rollis D,
    4. et al

    . Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007;62:870–77

    CrossRefPubMedWeb of Science
81. 81.↵
    1. Cannon DM,
    2. Carson RE,
    3. Nugent AC,
    4. et al

    . Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006;63:741–47

    CrossRefPubMedWeb of Science
82. 82.↵
    1. Meyer JH,
    2. Houle S,
    3. Sagrati S,
    4. et al

    . Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004;61:1271–79

    CrossRefPubMedWeb of Science
83. 83.↵
    1. Meyer JH,
    2. Wilson AA,
    3. Sagrati S,
    4. et al

    . Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826–35

    CrossRefPubMedWeb of Science
84. 84.↵
    1. Parsey RV,
    2. Ogden RT,
    3. Miller JM,
    4. et al

    . Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry 2010;68:170–78

    CrossRefPubMedWeb of Science
85. 85.↵
    1. Saijo T,
    2. Takano A,
    3. Suhara T,
    4. et al

    . Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635. Int J Neuropsychopharmacol 2010;13:785–91

    Abstract/FREE Full Text
86. 86.↵
    1. Meltzer CC,
    2. Price JC,
    3. Mathis CA,
    4. et al

    . Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 2004;29:2258–65

    CrossRefPubMedWeb of Science
87. 87.↵
    1. Hirvonen J,
    2. Karlsson H,
    3. Kajander J,
    4. et al

    . Decreased brain serotonin 5-HT1A receptor availability in medication-naïve patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol 2008;11:465–76

    Abstract/FREE Full Text
88. 88.↵
    1. Drevets WC,
    2. Thase ME,
    3. Moses-Kolko EL,
    4. et al

    . Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007;34:865–77

    CrossRefPubMedWeb of Science
89. 89.↵
    1. Miller JM,
    2. Brennan KG,
    3. Ogden TR,
    4. et al

    . Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009;34:2275–84

    CrossRefPubMedWeb of Science
90. 90.↵
    1. Sullivan GM,
    2. Ogden RT,
    3. Oquendo MA,
    4. et al

    . Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry 2009;66:223–30

    CrossRefPubMedWeb of Science
91. 91.↵
    1. Parsey RV,
    2. Oquendo MA,
    3. Ogden RT,
    4. et al

    . Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006;59:106–13

    CrossRefPubMedWeb of Science
92. 92.↵
    1. Mickey BJ,
    2. Ducci F,
    3. Hodgkinson CA,
    4. et al

    . Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J Neurosci 2008;28:11354–59

    Abstract/FREE Full Text
93. 93.↵
    1. Mintun MA,
    2. Sheline YI,
    3. Moerlein SM,
    4. et al

    . Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 2004;55:217–24

    CrossRefPubMedWeb of Science
94. 94.↵
    1. Sheline YI,
    2. Mintun MA,
    3. Moerlein SM,
    4. et al

    . Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry 2002;159:430–35

    CrossRefPubMedWeb of Science
95. 95.↵
    1. Bragulat V,
    2. Paillere-Martinot ML,
    3. Artiges E,
    4. et al

    . Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F] fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res 2007;154:115–24

    CrossRefPubMedWeb of Science
96. 96.↵
    1. Dougherty DD,
    2. Bonab AA,
    3. Ottowitz WE,
    4. et al

    . Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress Anxiety 2006;23:175–77

    CrossRefPubMed
97. 97.↵
    1. Cannon DM,
    2. Klaver JM,
    3. Peck SA,
    4. et al

    . Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [(11)C]NNC-112. Neuropsychopharmacology 2009;34:1277–87

    CrossRefPubMedWeb of Science
98. 98.↵
    1. Kano M,
    2. Fukudo S,
    3. Tashiro A,
    4. et al

    . Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 2004;20:803–10

    CrossRefPubMedWeb of Science
99. 99.↵
    1. Fujita M,
    2. Hines CS,
    3. Zoghbi SS,
    4. et al

    . Downregulation of brain phosphodiesterase type IV measured with (11)C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry 2012;72:548–54

    CrossRefPubMed
100. 100.↵
     1. Meyer JH,
     2. Ginovart N,
     3. Boovariwala A,
     4. et al

     . Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006;163:1594–602

     CrossRefPubMedWeb of Science
101. 101.↵
     1. Montgomery AJ,
     2. Stokes P,
     3. Kitamura Y,
     4. et al

     . Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord 2007;101:113–22

     CrossRefPubMed
102. 102.↵
     1. Meyer JH,
     2. Ginovart N,
     3. Boovariwala A,
     4. et al

     . Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006;63:1209–16

     CrossRefPubMedWeb of Science
103. 103.↵
     1. Meyer JH,
     2. Wilson AA,
     3. Sagrati S,
     4. et al

     . Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 2009;66:1304–12

     CrossRefPubMedWeb of Science
104. 104.↵
     1. Rosa-Neto P,
     2. Diksic M,
     3. Okazawa H,
     4. et al

     . Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004;61:556–63

     CrossRefPubMedWeb of Science
105. 105.↵
     1. Bhagwagar Z,
     2. Rabiner EA,
     3. Sargent PA,
     4. et al

     . Persistent reduction in brain serotonin 1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Biol Psychiatry 2004;9:386–92
106. 106.↵
     1. Yatham LN,
     2. Liddle PF,
     3. Lam RW,
     4. et al

     . Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry 2010;196:474–79

     Abstract/FREE Full Text
107. 107.↵
     1. Bhagwagar Z,
     2. Hinz R,
     3. Taylor M,
     4. et al

     . Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907. Am J Psychiatry 2006;163:1580–87

     CrossRefPubMedWeb of Science
108. 108.↵
     1. Lanzenberger R,
     2. Baldinger P,
     3. Hahn A,
     4. et al

     . Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry 2013;18:93–100

     CrossRefPubMedWeb of Science
109. 109.↵
     1. Saijo T,
     2. Takano A,
     3. Suhara T,
     4. et al

     . Electroconvulsive therapy decreases dopamine D(2) receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [11C]FLB 457. J Clin Psychiatry 2010;71:793–99

     CrossRefPubMedWeb of Science
110. 110.↵
     1. Moses-Kolko EL,
     2. Price JC,
     3. Thase ME,
     4. et al

     . Measurement of 5-HT1A receptor binding in depressed adults before and after anti-depressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 2007;61:523–30

     CrossRefPubMedWeb of Science
111. 111.↵
     1. Miller JM,
     2. Oquendo MA,
     3. Ogden RT,
     4. et al

     . Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res 2008;42:1137–44

     CrossRefPubMed
112. 112.↵
     1. Karlsson H,
     2. Hirvonen J,
     3. Kajander J,
     4. et al

     . Research letter: psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol Med 2010;40:523–28

     CrossRefPubMed
113. 113.↵
     1. Meyer JH,
     2. McMain S,
     3. Kennedy SH,
     4. et al

     . Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003;160:90–99

     CrossRefPubMedWeb of Science
114. 114.↵
     1. Bhagwagar Z,
     2. Murthy N,
     3. Selvaraj S,
     4. et al

     . 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry 2007;164:1858–65

     CrossRefPubMedWeb of Science
115. 115.↵
     1. Klumpers UM,
     2. Veltman DJ,
     3. Drent ML,
     4. et al

     . Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010;37:565–74

     CrossRefPubMed
116. 116.↵
     1. Lagopoulos J,
     2. Hermens DF,
     3. Tobias-Webb J,
     4. et al

     . In vivo glutathione levels in young persons with bipolar disorder: a magnetic resonance spectroscopy study. J Psychiatr Res 2013;47:412–17

     CrossRefPubMed
117. 117.
     1. Narayana PA,
     2. Johnston D,
     3. Flamig DP

     . In vivo proton magnetic resonance spectroscopy studies of human brain. Magn Reson Imaging 1991;9:303–08

     CrossRefPubMedWeb of Science